Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: Data on Korean patients obtained by the cabazitaxel compassionate-use program

Jae Lyun Lee, Se Hoon Park, Su Jin Koh, Se Hoon Lee, Yu Jung Kim, Yoon Ji Choi, Jihye Lee, Ho Yeong Lim

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: To report the efficacy and safety of using cabazitaxel plus prednisolone chemotherapy to treat Korean patients with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel therapy. Methods: This cohort study enrolled 26 mCRPC patients. Treatment consisted of 25 mg/m2 cabazitaxel that was intravenously administered every 3 weeks, in addition to twice-daily 5 mg prednisolone. Results: The median patient age was 67 years (range = 53-82), median Eastern Cooperative Oncology Group performance status was 1 (range = 0-2), Gleason score was ≥8 in 25 patients (96 %), and median serum prostate-specific antigen (PSA) was 95.3 ng/mL (interquartile range = 9.1-297.7). A total of 180 treatment cycles were administered, and a median of five cycles were administered per patient (range = 1-23). A PSA response was observed in 32 % of evaluable patients. Tumor response was evaluated in eight patients, and three and four patients achieved partial response and stable disease, respectively. Over a median follow-up duration of 23.4 months (95 % CI 11.1-35.6), median time to treatment failure was 4.2 months (95 % CI 1.8-6.6) and median time to progression was 8.5 months (95 % CI 3.0-13.1). Median overall survival was 16.5 months (95 % CI 12.1-20.9). Grade 3 or worse febrile neutropenia developed in eight patients (31 %) and neutropenic infection in four patients (15 %). Conclusion: Cabazitaxel plus prednisolone chemotherapy can be used to treat Korean mCRPC patients. Prophylactic growth factor support should be considered for patients at high risk of neutropenic fever or infection.

Original languageEnglish
Pages (from-to)1005-1013
Number of pages9
JournalCancer Chemotherapy and Pharmacology
Volume74
Issue number5
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Compassionate Use Trials
Chemotherapy
Castration
Prednisolone
docetaxel
Prostate-Specific Antigen
Carcinoma
Safety
Drug Therapy
Oncology
Tumors
Intercellular Signaling Peptides and Proteins
Prostatic Neoplasms
cabazitaxel
Febrile Neutropenia
Neoplasm Grading
Infection
Treatment Failure

Keywords

  • Cabazitaxel
  • Castration-resistant prostate cancer
  • Chemotherapy
  • Febrile neutropenia
  • Prednisolone

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma : Data on Korean patients obtained by the cabazitaxel compassionate-use program. / Lee, Jae Lyun; Park, Se Hoon; Koh, Su Jin; Lee, Se Hoon; Kim, Yu Jung; Choi, Yoon Ji; Lee, Jihye; Lim, Ho Yeong.

In: Cancer Chemotherapy and Pharmacology, Vol. 74, No. 5, 01.01.2014, p. 1005-1013.

Research output: Contribution to journalArticle

@article{424c2b5e690e4d51be2d7086aee5ad33,
title = "Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: Data on Korean patients obtained by the cabazitaxel compassionate-use program",
abstract = "Purpose: To report the efficacy and safety of using cabazitaxel plus prednisolone chemotherapy to treat Korean patients with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel therapy. Methods: This cohort study enrolled 26 mCRPC patients. Treatment consisted of 25 mg/m2 cabazitaxel that was intravenously administered every 3 weeks, in addition to twice-daily 5 mg prednisolone. Results: The median patient age was 67 years (range = 53-82), median Eastern Cooperative Oncology Group performance status was 1 (range = 0-2), Gleason score was ≥8 in 25 patients (96 {\%}), and median serum prostate-specific antigen (PSA) was 95.3 ng/mL (interquartile range = 9.1-297.7). A total of 180 treatment cycles were administered, and a median of five cycles were administered per patient (range = 1-23). A PSA response was observed in 32 {\%} of evaluable patients. Tumor response was evaluated in eight patients, and three and four patients achieved partial response and stable disease, respectively. Over a median follow-up duration of 23.4 months (95 {\%} CI 11.1-35.6), median time to treatment failure was 4.2 months (95 {\%} CI 1.8-6.6) and median time to progression was 8.5 months (95 {\%} CI 3.0-13.1). Median overall survival was 16.5 months (95 {\%} CI 12.1-20.9). Grade 3 or worse febrile neutropenia developed in eight patients (31 {\%}) and neutropenic infection in four patients (15 {\%}). Conclusion: Cabazitaxel plus prednisolone chemotherapy can be used to treat Korean mCRPC patients. Prophylactic growth factor support should be considered for patients at high risk of neutropenic fever or infection.",
keywords = "Cabazitaxel, Castration-resistant prostate cancer, Chemotherapy, Febrile neutropenia, Prednisolone",
author = "Lee, {Jae Lyun} and Park, {Se Hoon} and Koh, {Su Jin} and Lee, {Se Hoon} and Kim, {Yu Jung} and Choi, {Yoon Ji} and Jihye Lee and Lim, {Ho Yeong}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00280-014-2579-5",
language = "English",
volume = "74",
pages = "1005--1013",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma

T2 - Data on Korean patients obtained by the cabazitaxel compassionate-use program

AU - Lee, Jae Lyun

AU - Park, Se Hoon

AU - Koh, Su Jin

AU - Lee, Se Hoon

AU - Kim, Yu Jung

AU - Choi, Yoon Ji

AU - Lee, Jihye

AU - Lim, Ho Yeong

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose: To report the efficacy and safety of using cabazitaxel plus prednisolone chemotherapy to treat Korean patients with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel therapy. Methods: This cohort study enrolled 26 mCRPC patients. Treatment consisted of 25 mg/m2 cabazitaxel that was intravenously administered every 3 weeks, in addition to twice-daily 5 mg prednisolone. Results: The median patient age was 67 years (range = 53-82), median Eastern Cooperative Oncology Group performance status was 1 (range = 0-2), Gleason score was ≥8 in 25 patients (96 %), and median serum prostate-specific antigen (PSA) was 95.3 ng/mL (interquartile range = 9.1-297.7). A total of 180 treatment cycles were administered, and a median of five cycles were administered per patient (range = 1-23). A PSA response was observed in 32 % of evaluable patients. Tumor response was evaluated in eight patients, and three and four patients achieved partial response and stable disease, respectively. Over a median follow-up duration of 23.4 months (95 % CI 11.1-35.6), median time to treatment failure was 4.2 months (95 % CI 1.8-6.6) and median time to progression was 8.5 months (95 % CI 3.0-13.1). Median overall survival was 16.5 months (95 % CI 12.1-20.9). Grade 3 or worse febrile neutropenia developed in eight patients (31 %) and neutropenic infection in four patients (15 %). Conclusion: Cabazitaxel plus prednisolone chemotherapy can be used to treat Korean mCRPC patients. Prophylactic growth factor support should be considered for patients at high risk of neutropenic fever or infection.

AB - Purpose: To report the efficacy and safety of using cabazitaxel plus prednisolone chemotherapy to treat Korean patients with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel therapy. Methods: This cohort study enrolled 26 mCRPC patients. Treatment consisted of 25 mg/m2 cabazitaxel that was intravenously administered every 3 weeks, in addition to twice-daily 5 mg prednisolone. Results: The median patient age was 67 years (range = 53-82), median Eastern Cooperative Oncology Group performance status was 1 (range = 0-2), Gleason score was ≥8 in 25 patients (96 %), and median serum prostate-specific antigen (PSA) was 95.3 ng/mL (interquartile range = 9.1-297.7). A total of 180 treatment cycles were administered, and a median of five cycles were administered per patient (range = 1-23). A PSA response was observed in 32 % of evaluable patients. Tumor response was evaluated in eight patients, and three and four patients achieved partial response and stable disease, respectively. Over a median follow-up duration of 23.4 months (95 % CI 11.1-35.6), median time to treatment failure was 4.2 months (95 % CI 1.8-6.6) and median time to progression was 8.5 months (95 % CI 3.0-13.1). Median overall survival was 16.5 months (95 % CI 12.1-20.9). Grade 3 or worse febrile neutropenia developed in eight patients (31 %) and neutropenic infection in four patients (15 %). Conclusion: Cabazitaxel plus prednisolone chemotherapy can be used to treat Korean mCRPC patients. Prophylactic growth factor support should be considered for patients at high risk of neutropenic fever or infection.

KW - Cabazitaxel

KW - Castration-resistant prostate cancer

KW - Chemotherapy

KW - Febrile neutropenia

KW - Prednisolone

UR - http://www.scopus.com/inward/record.url?scp=84919907061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919907061&partnerID=8YFLogxK

U2 - 10.1007/s00280-014-2579-5

DO - 10.1007/s00280-014-2579-5

M3 - Article

C2 - 25193433

AN - SCOPUS:84919907061

VL - 74

SP - 1005

EP - 1013

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -